328.51
2.17 (0.66%)
| Penutupan Terdahulu | 326.34 |
| Buka | 329.39 |
| Jumlah Dagangan | 103,813 |
| Purata Dagangan (3B) | 190,639 |
| Modal Pasaran | 9,182,446,592 |
| Harga / Pendapatan (P/E Ke hadapan) | 30.12 |
| Harga / Jualan (P/S) | 3.76 |
| Harga / Buku (P/B) | 1.28 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 13 Feb 2025 - 17 Feb 2025 |
| Margin Keuntungan | -30.18% |
| Margin Operasi (TTM) | 9.94% |
| EPS Cair (TTM) | -28.09 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 2.80% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | 514.70% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 18.54% |
| Nisbah Semasa (MRQ) | 6.14 |
| Aliran Tunai Operasi (OCF TTM) | 412.00 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 91.24 M |
| Pulangan Atas Aset (ROA TTM) | 1.86% |
| Pulangan Atas Ekuiti (ROE TTM) | -9.79% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Medical Devices (US) | Bercampur | Bercampur |
| Medical Devices (Global) | Bercampur | Bercampur | |
| Stok | Bio-Rad Laboratories, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -1.0 |
| Purata Bergerak Teknikal | 3.5 |
| Osilator Teknikal | 2.0 |
| Purata | 2.38 |
|
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing. |
|
| Sektor | Healthcare |
| Industri | Medical Devices |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 15.57% |
| % Dimiliki oleh Institusi | 87.67% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 481.00 (RBC Capital, 46.42%) | Beli |
| Median | 465.50 (41.70%) | |
| Rendah | 450.00 (Citigroup, 36.98%) | Beli |
| Purata | 465.50 (41.70%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 351.90 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| RBC Capital | 09 Dec 2024 | 481.00 (46.42%) | Beli | 345.60 |
| 31 Oct 2024 | 469.00 (42.77%) | Beli | 358.19 | |
| Citigroup | 31 Oct 2024 | 450.00 (36.98%) | Beli | 358.19 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 08 Jan 2025 | Pengumuman | Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests |
| 02 Jan 2025 | Pengumuman | Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan's 43rd Annual Healthcare Conference |
| 21 Nov 2024 | Pengumuman | Bio-Rad’s Management to Host Investor Meetings at Citi's 2024 Global Healthcare Conference |
| 31 Oct 2024 | Pengumuman | Bio-Rad's Management to Participate in Fireside Chat During UBS Global Healthcare Conference |
| 30 Oct 2024 | Pengumuman | Bio-Rad Reports Third-Quarter 2024 Financial Results |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |